Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
44
Participants
Timeline
Start Date
July 3, 2018
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Conditions
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and NeckResectable Cutaneous Squamous Cell Carcinoma of the Head and NeckStage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
BIOLOGICAL
Cemiplimab
Given IV
Trial Locations (1)
77030
M D Anderson Cancer Center, Houston
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
M.D. Anderson Cancer Center
OTHER
NCT03565783 - Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery | Biotech Hunter | Biotech Hunter